Related Experiment Videos
[Analysis on point mutation of the CDKN2/p16 gene in lung cancer]
Changqing Su1, Yukun Ye, Dong Wang
1Cancer Center of PLA, Nanjing 81 Hospital, Nanjing, Jiangsu, 210002 P. R. China. sucq@jlonline.com
Objective:
To study the status of CDKN2/p16 gene point mutation in lung cancer.
Methods:
Polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and sequencing were used to detect the point mutation of CDKN2/p16 gene exon 2 in 89 cases of lung cancer.
Results:
In 69 cases of the lung cancer without deletion of CDKN2/p16 gene exon 2, 16 cases were found to have suspicious abnormality of CDKN2/p16 gene exon 2 by PCR-SSCP, and in these 16 cases, 9 were found to harbor point mutations of CDKN2/p16 gene exon 2 by automated sequencing analysis.
Conclusion:
The point mutation is one of the mechanisms for CDKN2/p16 gene inactivation, but it is not the chief mechanism. The inactivation of CDKN2/p16 gene aroused by point mutation plays a role to some extent in the genesis and progression of lung cancer.